Back to top
more

Assertio (ASRT)

(Real Time Quote from BATS)

$1.09 USD

1.09
62,046

-0.02 (-1.80%)

Updated Aug 14, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

by Zacks Equity Research

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales

by Zacks Equity Research

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.

Assertio (ASRT) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ASRT vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Top Ranked Value Stocks to Buy for September 9th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, September 9th

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Assertio Therapeutics Enters Oversold Territory

by Zacks Equity Research

Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ASRT vs. PCRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Assertio (ASRT) Q2 Earnings Beat Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ASRT or AMRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASRT vs. AMRX: Which Stock Is the Better Value Option?

La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

by Zacks Equity Research

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

Savara Plunges on Failure of Late-Stage Study on Molgradex

by Zacks Equity Research

Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

BioCryst Down Despite Hereditary Angioedema Study Meets Goal

by Zacks Equity Research

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

ASSERTIO THERAPEUTICS Enters Oversold Territory

by Zacks Equity Research

ASSERTIO THERAPEUTICS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ASRT) Outperforming Other Medical Stocks This Year?

Assertio (ASRT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 27.78% and 4.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

by Zacks Equity Research

Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

Will Assertio Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Assertio Therapeutics.

Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

by Zacks Equity Research

Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 13th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday